Találati lista | Tudóstér

001-es BibID:	BIBFORM075566
Első szerző:	Nagy Gábor (laboratóriumi szakorvos, laboratóriumi hematológus és immunológus)
Cím:	Monitoring of drug level and anti-drug antibody production during vedolizumab therapy in patients with inflammatory bowel disease / G. Nagy, É. Török, K. Palatka, Z. Kébel, P. Antal-Szalmás
Dátum:	2018
Megjegyzések:	Integrin ?4?7 is expressed on gut-specific lymphocytes and plays a pivotal role in their migration to the intestine. Vedolizumab (VDZ, trade name Entyvio), a humanized monoclonal IgG1 antibody to the ?4?7 integrin blocks their adhesion to the gut vascular endothelium. In 2014 Entyvio was approved for patients with ulcerative colitis (UC) and Crohn's disease (CD) in Hungary. Our aim was to find and evaluate laboratory tests capable of measuring vedolizumab and anti-vedolizumab antibody (AVA) levels. After overviewing the available methods, LISA-TRACKER Duo Vedolizumab ELISA kit (ref: LTV 005, TheraDiag, Croissy-Beaubourg, France) was chosen. Seventeen samples of 15 patients (9 UC/6 CD) were analyzed. Mean VDZ levels were 18.2 ?g/mL and 7.4 ?g/mL in patients with UC and CD, respectively (p=0.242). Drug levels were significantly higher in patients on concomitant immune modulating therapy (16.9 ?g/mL vs 3.9 ?g/mL, p=0.033). There was no significant correlation between drug concentrations and CRP or disease activity scores. Anti-vedolizumab antibody was not detected in any of the patients (0/15) in accordance with the approximately 4% AVA positivity reported in vedolizumab immunogenicity studies (p=0.430). Five patients had drug levels under the measuring range of the test (<2 ?g/mL) suggesting the possibility of having low affinity anti-drug antibodies not detected by the bridging ELISA method used. In conclusion, LISA-TRACKER Duo Vedolizumab ELISA kit seems to be appropriate to monitor drug and anti-drug antibody levels in patients with inflammatory bowel disease. However, insensitivity of the ELISA methods for detecting low affinity anti-drug antibody may limit its use to determine immunogenicity of vedolizumab.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idézhető absztrakt
Megjelenés:	Clinical Chemistry and Laboratory Medicine. - 56 : 9 (2018), p. eA162. -
További szerzők:	Török Éva Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Kébel Z. Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM110793
035-os BibID:	(WoS)000963794300001 (Scopus)85166473548
Első szerző:	Palatka Réka (orvos)
Cím:	Chronic inflammatory intestinal disorders in hidradenitis suppurativa / Palatka Réka, Janka Eszter Anna, Soltész Lilla, Szabó Imre Lőrinc, Kapitány Anikó, Dajnoki Zsolt, Emri Gabriella, Nagy Gábor, Palatka Károly, Zouboulis Christos C., Szegedi Andrea, Gáspár Krisztián
Dátum:	2023
ISSN:	1018-8665
Megjegyzések:	Background: Intestinal symptoms are common in patients with hidradenitis suppurativa (HS). HS patients may experience a broad spectrum of chronic inflammatory intestinal disorders (CIID), not exclusive to inflammatory bowel diseases, which are diagnosed by colonoscopy and intestinal biopsies. The frequency of CIID in patients with HS has not been investigated.Objective: The objectives of this study were to determine the occurrence of CIID in HS and characterise this clinical population. Furthermore, the feasibility of using fecal calprotectin (FC) test or anti-Saccharomyces cerevisiae antibody (ASCA) levels to assess the colonic inflammation of CIID in HS patients was investigated. Methods: All newly diagnosed and untreated HS patients (n=74) were referred to a gastroenterologist for FC followed by colonoscopy after informed consent. C-reactive protein (CRP), white blood cell count, nucleotide-binding-oligomerisation-domain-containing-protein-2 (NOD2) polymorphism, and ASCA levels were measured. Patients were divided into HS-only and HS with CIID (HS+CIID) groups, based on the absence or presence of CIID. Laboratory and clinical parameters (age, gender, HS onset, clinical stage, family history, body mass index (BMI), smoking) were compared between the groups.Results: Thirteen patients complained gastrointestinal symptoms prior to any examination, including 11 in the HS+CIID group. The CIID frequency in HS was 28.4% (n=21/74), based on colonoscopy and histology. Significantly more patients had severe disease state in the HS+CIID group compared with the HS-only group, and BMI was significantly lower in the HS+CIID group (28.20 +/- 5.58 vs. 32.74 +/- 6.45, p=0.006). FC positivity occurred significantly more in HS+CIID patients compared with HS-only patients (90.48% vs. 3.77%, p<0.001), and ASCA IgG levels were significantly elevated in HS+CIID patients (22.08 +/- 23.07 vs 8.41 +/- 10.94 U/mL, p=0.001). The FC test identified HS+CIID patients with 96.23% specificity and 91.3% sensitivity, while ASCA displayed 77.8% sensitivity and 76.3% specificity. Blood count, CRP and the presence of NOD2 polymorphisms were indifferent between the two groups. Conclusion: A high frequency of CIID was detected in the examined HS population. The non-invasive FC test has high sensitivity and specificity for diagnosing CIID in HS patients. Concomitant CIID and HS may indicate the need for an early-start for biological treatment.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Dermatology. - 239 : 4 (2023), p. 592-600. -
További szerzők:	Janka Eszter Anna (1989-) (bőrgyógyász, népegészségügyi szakember) Soltész Lilla (1994-) (orvos) Szabó Imre Lőrinc (1987-) (általános orvos) Kapitány Anikó (1979-) (molekuláris biológus) Dajnoki Zsolt (1985-) (molekuláris biológus) Emri Gabriella (1972-) (bőrgyógyász, allergológus, onkológus) Nagy Gábor (1974-) (laboratóriumi szakorvos, laboratóriumi hematológus és immunológus) Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Zouboulis, Christos C. (1960-) (bőrgyógyász) Szegedi Andrea (1964-) (bőrgyógyász) Gáspár Krisztián (1974-) (bőrgyógyász)
Pályázati támogatás:	K-128250 OTKA K-142348 OTKA PD-131689 OTKA EFOP-3.6.1-16-2016-00022 EFOP ÚNKP-21-5 Egyéb ÚNKP-22-4 Egyéb ERN Skin - ALLOCATE Skin Group Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: